Product Description
alpha-tocotrienol for health status and quality of life measures, cognitive functioning, oxidative stress, inflammation markers and other symptoms effects on skin, sleep and vision in the elderly. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01953172)
Mechanisms of Action: FAK Inhibitor, VEGFR3 Inhibitor, FLT3 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Unilever
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01953172 |
FDS-NBU-1034 | N/A |
Terminated |
Inflammation|Oxidative Stress |
2014-09-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|